EGFR and non-small cell lung carcinoma: And the RELAY trial showed benefit in prognosis of EGFR‐mutated metastatic non‐small‐cell lung cancer (NSCLC) patients who were treated with dual EGFR‐VEGF inhibition, comparing with those who were treated with placebo and anti‐EGFR therapy.20